興科蓉醫藥(06833.HK)與北京諾康達就開發注射用聚己內酯微球面部填充劑及其材料訂立主合作協議及技術開發協議
格隆匯9月9日丨興科蓉醫藥(06833.HK)公吿,於2021年9月9日,公司及其全資附屬公司與北京諾康達就開發注射用聚己內酯微球面部填充劑及其材料訂立主合作協議及技術開發協議,代價為人民幣8850萬元。
四川興科蓉為於中國註冊成立的有限責任公司,併為集團的全資附屬公司。其主要於中國為進口藥品提供綜合性營銷、推廣及渠道管理服務以及提供新藥品的研發及生物技術產品的技術開發。
憑藉集團於進口藥品供應方面的專長及經驗,集團擬開發其醫療美容產業鏈,並逐步建立藥品及醫療美容產品兩個業務分部,作為其業務發展方向。因此,為抓住醫療美容產品的市場機遇,集團擬利用北京諾康達於醫藥材料及製劑的研發能力,開發注射用聚己內酯微球面部填充劑及材料,以拓寬集團的收入來源並豐富其產品種類。
董事相信,該技術開發項目可為集團在設立自身研發中心時建立專長及資源提供基礎,以逐步開發、生產及銷售醫療美容產品。此外,利用集團完善的醫藥營銷及推廣渠道,董事認為,這將為該等新醫療美容產品的營銷及銷售帶來協同效應,讓集團可實現長期收益增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.